In Depth 20 Jun 2022 France’s grand plan to lead Europe’s biotech innovation landscape For decades, the French biotech scene has been catching up to key strongholds such as the U.S. and U.K. In the aftermath of the COVID-19 pandemic, the French government last year bet €7.5 billion on an ambitious project to turn France into Europe’s health innovation magnet by 2030. France is one of Europe’s most established […] June 20, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022 ImCheck raises €96M in funding round French biotech company ImCheck has announced funding of €96 million ($101.5 million) to investigate antibody drugs with the ability to activate the powerful immune cells called gamma delta T (gdT). The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development […] June 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022Beyond Biotech podcast 1: Forbion, OMass, PharNext It’s the first official Beyond Biotech podcast! And this week, we have three interviews. We talked with Ros Deegan, CEO of OMass; David Solomon, CEO of PharNext; and two people from Forbion, Sander Slootweg, managing partner, and Dirk Mertens, general partner. Forbion European life sciences venture capital firm Forbion, has announced the first €470M ($500M) […] June 17, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Taiwanese company sells knee pain drug for $30 million A clinical stage pharma company specializing in developing nanomedicines will receive $30 million in exchange for rights to an injectable treatment for osteoarthritis (OA). In one of the largest deals in Taiwan’s biotech sector, TLC Biosciences will receive the upfront payment with potential to earn a further $110m if the treatment targeting knee pain is […] June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Gimv creates new fund for life science companies European investment company Gimv has launched its fifth investment platform with a focus on venture capital investments in innovative life sciences companies. Gimv said after growth in its existing healthcare platform, a dedicated life sciences platform will strengthen its role in the international life science venture capital ecosystem. The company added its key investment focus […] June 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […] June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Molecular farming company Moolec Science joins with LightJump to list on Nasdaq Moolec Science Ltd., a science-based food ingredient company, and LightJump Acquisition Corp., a publicly traded special purpose acquisition company, have agreed to a business combination that would result in Moolec Science SA, a newly-created affiliate of Moolec incorporated in Luxembourg, becoming a publicly listed company. Moolec and U.S.-based LightJump will ultimately become wholly-owned subsidiaries of […] June 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Clean and green: Unilever and Geno launch $120m palm oil alternatives venture Unilever and U.S. biotech company Genomatica (Geno) are working on a plan to scale and commercialize alternatives to palm oil and fossil fuel-derived cleansing ingredients. The companies said due to growing demand for sustainably-sourced palm oil, they aim to deliver new responsibly-sourced palm oil alternatives to the market. With $120m jointly invested in the newly-formed […] June 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance phase I/II programs in Europe and the U.S., using TILT-123 plus […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Sling Therapeutics emerges with $35M to tackle thyroid eye disease Michigan-based biopharma company Sling Therapeutics, Inc. has launched, with $35 million in series A financing led by TPG’s The Rise Fund. The company is focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The funds support a phase 2b clinical trial evaluating its investigational drug, linsitinib. “We […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Eurocine Vaccines expands portfolio to develop HSV-2 vaccine Swedish company Vaccines AB (Eurocine Vaccines) has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2), based on technologies developed by Swiss biotech company Redbiotec. The agreement covers both an mRNA […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Biotech companies to benefit from Third Rock Ventures $1.1B fund U.S. company Third Rock Ventures has closed Third Rock Ventures Fund VI, raising $1.1 billion. Fund VI will continue Third Rock’s core strategy to discover, launch and build new companies focused on improving the lives of patients. “An important differentiator for Third Rock is the strength and maturity of our ideation ecosystem,” said Reid Huber, […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email